Opexa Therapeutics, Inc. (NASDAQ:ACER) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Monday.

Opexa Therapeutics (NASDAQ:ACER) opened at 14.90 on Monday. The firm has a 50-day moving average of $10.40 and a 200-day moving average of $8.29. The stock’s market capitalization is $11.01 million. Opexa Therapeutics has a 1-year low of $5.21 and a 1-year high of $45.62.

TRADEMARK VIOLATION WARNING: This news story was reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.watchlistnews.com/opexa-therapeutics-inc-acer-stock-rating-lowered-by-valuengine/1606717.html.

About Opexa Therapeutics

Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.

Receive News & Ratings for Opexa Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.